P - Pandora Media, Inc. – Shares in Pandora are spiking today, up as much as 8.3% in the early going to a one-month high of $17.78, after the stock was raised to ‘Outperform’ from ‘Market Perform’ at Cowen with a 12-month target price of $22.00. Options traders snapped up July expiry calls straight out of the gate this morning, initiating bullish positions that benefit from continued gains in the price of the underlying during the next few weeks. The Jul $17 strike options attracted the most volume in early trading, with roughly 3,600 calls in play versus open interest of 2,722 contracts as of 11:00 a.m. ET. Most of the calls appear to have been purchased by one strategist for a premium of $1.25 per contract. The call buyer makes money at expiration next month as long as Pandora’s shares rise 2.6% over today’s high of $17.78 to exceed the effective breakeven price of $18.25. Pandora bulls are also buying Jul $18 and $19 strike calls this morning, with roughly 900 of the $18 strike contracts purchased at an average premium of $0.72, and roughly 500 of the $19 strike calls picked up at an average premium of $0.37 apiece. Shares in Pandora are up 95% since the start of 2013.
APOL - Apollo Group, Inc. – Declines in new enrollments and slumping third-quarter profits reported by the University of Phoenix operator after the close on Tuesday sent shares in the name down substantially on Wednesday. The stock, which will relinquish its spot in the S&P 500 Index and make its way into the S&P Midcap 400 later in the week, fell as much as 8.9% to $17.66 in early trading. Contrarian traders positioning for shares in Apollo to snap back in the near term appear to be buying July expiry calls today. The Jul $19 and $20 strike calls were active in the early going this morning, with roughly 950 of the $19 calls purchased for an average premium of $0.71…
JCP - J.C. Penney Co., Inc. – Upside call buying in weekly options on J.C. Penney this morning suggest some traders are positioning for shares in the department store operator to rally during the final week of the year. Shares in JCP are up 2.65% at $20.11 as of 11:05 a.m. in New York, but are down more than 40% since the start of 2012. Fresh interest in weekly calls looks for shares in the retailer to extend this morning’s gains when the market reopens after the Christmas holiday. Volume is heaviest at the Dec. 28 ’12 $20 strike, where upwards of 3,500 calls changed hands against open interest of 1,469 contracts. It looks like most of the volume was purchased for an average premium of $0.68 each in the early going. In-the-money call buyers stand ready to profit at expiration this week should shares in JCP rally another 2.8% to top the average breakeven price of $20.68. Bullish positioning spread to the Dec. 28 ’12 $20.5 and $21 strikes, with more than 650 contracts purchased at each strike for average premiums of $0.45 and $0.28 apiece, respectively. Finally, around 275 of the Dec. 28 ’12 $22 strike calls were picked up at an average premium of $0.20 each, thus positioning buyers to profit in the event of a more than 10% move in the share price to $22.20 by expiration.
RPTP - Raptor Pharmaceutical Corp. – Shares in Raptor Pharmaceutical Corp. fell sharply in after-hours trading on Friday after the company said the U.S. Food and Drug Administration needs more time to complete its review of Raptor’s New Drug Application (NDA) for RP103 (PROCYSBI™), a potential treatment for nephropathic cystinosis, according to a press release issued by Raptor on Friday. Shares continue to slide on Monday morning, down 7% at $5.34 as of 11:25 a.m. ET. One or more traders preparing for Raptor’s shares to continue to slide in the New Year snapped up put options in the February expiry. Traders exchanged more than 750 puts at the Feb.…
ESRX - Express Scripts, Inc. – Sizable bullish bets in long-dated call and put options on the pharmacy benefit management services provider suggest shares in Express Scripts may sky-rocket over the next year and a half. Similar options combination plays were initiated at the end of last week following news Express Scripts agreed to purchase rival Medco Health Solutions Inc. for $29.1 billion in a deal that would make the company the largest U.S. pharmacy benefits manager. Shares in Saint Louis, MO-based Express Scripts slipped 0.60% during the first half of the trading session to $56.95 as of 11:50 am ET. The price of the underlying rallied as much as 12.0% to $57.47 on news of the merger agreement. Large prints in January 2013 contract on Friday appeared to be the work of an investor selling blocks of puts to partially finance the purchase of a bull call spread. The strategist responsible for the four-legged transaction rakes in maximum available profits on the trade if shares in ESRX top $70.00 at expiration. Heavy trading in the same expiry within the first hour of the opening bell indicates another options player may see shares in Express Scripts soaring to $80.00 during the next 18 months. The more recent long-term bullish combo trade on Express Scripts differs somewhat from that observed on Friday, but both transactions are looking for shares to reach all-time highs. The investor this morning appears to have sold 8,000 puts at the Jan. 2013 $42.5 strike for a premium of $2.19 each, spread against the purchase of an 8,000-lot Jan. 2013 $65/$80 call spread at a net premium of $3.34 per contract. The sale of the put options reduces the net cost of the three-way transaction to $1.15 per contract, thus positioning the investor to profit should shares in Express Scripts surge 16.2% over the current price of $56.95 to surpass the effective breakeven point to the upside at $66.15 at Jan. 2013 expiration.…
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at firstname.lastname@example.org with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
It is not a good morning for Bill Ackman's Pershing Square or Bruce Berkowitz's Fairholme Capital, or the US government for that matter, of course, which happen to be the three largest investors in Fannie Mae:
The reason: FNM stock, which at last check, was crashing by nearly 60%.
So why is FNM plunging? Perhaps a better question is why they soared as much as they did in the first place.
For the answer we go to Bill Ackman and his jolly copycat groupies. As ...
Oil crashed today, with crude oil prices dropping from around $95 to $91 in a matter of minutes.
There were various theories for why, but the most compelling one is that there seems to be a lot more production than estimated.
Morgan Stanley sent out a note this evening from analyst Adam Longson that contains this table of production numbers/estimates for key producers. The key thing is that production is on the rise almost everywhere. Check out Libya, where output for the month surged to its highest level of the year. Everyone was freaking out a...
The CBOE Vix Index topped 17.0 and the highest level since early-August on Monday morning amid declines in U.S. equities to start the trading week. The volatility index is off its earlier highs to trade 5.0% higher on the session at 15.65 as of 11:30 am ET. Options volume on the VIX is hovering near 360,000 contracts, or just more than 50% of the average daily reading of around 660,000 contracts. Calls are far more active than put options, as evidenced by the call/put ratio up above 4.2 in morning trading, perhaps as some traders position for volatility to stick around.
Large call spreads traded on the VIX today caught our attention as one big optio...
Yes, the market showed significant weakness last week for the first time in quite a while. In fact, the Dow Jones Industrial Average moved triple digits each day. But it was all quite predictable, as I suggested in last week's article, and certainly nothing to worry about. Now the market appears to be poised for a modest technical rebound, and longer term, U.S. equities should be in good shape for a year-end rally. However, I still believe more downside is in order before any new highs are challenged. Moreover, market breadth is important for a sustained bull run, so the challenge for investors will be to put together broader bullish conviction, including the small caps.
In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, re...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
Ebola is spreading too quickly for Ebola-vaccine makers to conduct typical studies of safety and efficacy on experimental vaccines. Instead, vaccines will be tested for basic safety, but then deployed with protocols devised now in order to test for efficacy essentially on the field. Testing has to be expedited because the situation in West Africa gets worse every day while there are no approved vaccines or other treatments.
The chart below is from a paper in the New England Journal of Medicine showing estimates of the virus's trajectory projecting out to November 1, 2014. If current trends continue...
Despite the various opinions on Bitcoin, there is no question as to its ultimate value: its ability to bypass government restrictions, including economic embargoes and capital controls, to transmit quasi-anonymous money to anyone anywhere.
Opinions differ as to what constitutes "money."
The English word "money" derives from the Latin word "moneta," which means to "mint." Historically, "money" was minted in the form of precious metals, most notably gold and silver. Minted metal was considered "money" because it possessed luster, was scarce, and had perceive...
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well PSW Subscribers....I am still here, barely. From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.
First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices. Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment. Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer. For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither MaddJack Enterprises, LLC
d/b/a PhilStockWorld (PSW) nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.